David L. Hava

3.9k total citations · 2 hit papers
41 papers, 2.9k citations indexed

About

David L. Hava is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Immunology. According to data from OpenAlex, David L. Hava has authored 41 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Epidemiology and 10 papers in Immunology. Recurrent topics in David L. Hava's work include Pneumonia and Respiratory Infections (9 papers), Inhalation and Respiratory Drug Delivery (7 papers) and Streptococcal Infections and Treatments (6 papers). David L. Hava is often cited by papers focused on Pneumonia and Respiratory Infections (9 papers), Inhalation and Respiratory Drug Delivery (7 papers) and Streptococcal Infections and Treatments (6 papers). David L. Hava collaborates with scholars based in United States, United Kingdom and Germany. David L. Hava's co-authors include Andrew Camilli, Michael B. Brenner, Maaike van Zon, Nicole N. van der Wel, Peter J. Peters, Donna Fluitsma, Jason Pierson, D. Scott Merrell, Sang Ho Lee and Matthew K. Waldor and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

David L. Hava

41 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

M. tuberculosis and M. leprae Translocate from the Phagolysosome to the Cytosol in Myeloid Cells

2007 734 citations Nicole N. van der Wel, David L. Hava et al. Cell profile →
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

2023 84 citations Jason J. Luke, Sarina A. Piha‐Paul et al. Clinical Cancer Research profile →

Peers

David L. Hava

EPIDE

IMMUN

PHEOH

Peadar Ó Gaora Ireland

Nemani V. Prasadarao United States

Vijay Pancholi United States

Sheila Sturgill-Koszycki United States

Letícia A. M. Carneiro Brazil

Jörn Coers United States

Hiroshi Ashida Japan

Dlawer A. A. Ala’Aldeen United Kingdom

Christina L. Stallings United States

Teresa L. M. Thurston United Kingdom

Peadar Ó Gaora Ireland

David L. Hava

697 ×0.6

EPIDE

1.3k ×1.4

926 ×1.1

898 ×1.3

IMMUN

537 ×1.2

PHEOH

Citations per year, relative to David L. Hava David L. Hava (= 1×) peers Peadar Ó Gaora

Countries citing papers authored by David L. Hava

Since Specialization

Citations

This map shows the geographic impact of David L. Hava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Hava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Hava more than expected).

Fields of papers citing papers by David L. Hava

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Hava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Hava. The network helps show where David L. Hava may publish in the future.

Co-authorship network of co-authors of David L. Hava

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Hava. A scholar is included among the top collaborators of David L. Hava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Hava. David L. Hava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perreault, Mylène, Michael J. James, Sean L. Cotton, et al.. (2024). The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers. Cell Host & Microbe. 32(3). 382–395.e10. 23 indexed citations

Zeng, Su-Ling, Yanhan Wang, Yi Duan, et al.. (2023). Engineered bacteria producing aryl‐hydrocarbon receptor agonists protect against ethanol‐induced liver disease in mice. Alcohol Clinical and Experimental Research. 47(5). 856–867. 27 indexed citations

Luke, Jason J., Sarina A. Piha‐Paul, Theresa Medina, et al.. (2023). Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical Cancer Research. 29(13). 2435–2444. 84 indexed citations breakdown →

Lubkowicz, David, Michael J. James, Ron B. Shmueli, et al.. (2022). An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria. Molecular Systems Biology. 18(3). e10539–e10539. 35 indexed citations

Edwards, David A., Anthony J. Hickey, Richard Batycky, et al.. (2020). A New Natural Defense Against Airborne Pathogens. SHILAP Revista de lepidopterología. 1. e5–e5. 12 indexed citations

Hava, David L., Patrick W. Johnson, Aidan K. Curran, et al.. (2019). A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. British Journal of Clinical Pharmacology. 86(4). 723–733. 23 indexed citations

Kuehl, Philip J., Ramesh Chand, Jacob D. McDonald, David L. Hava, & Wesley DeHaan. (2019). Pulmonary and Regional Deposition of Nebulized and Dry Powder Aerosols in Ferrets. AAPS PharmSciTech. 20(6). 242–242. 6 indexed citations

Kenyon, Jennifer, et al.. (2018). Inhaled calcium salts inhibit tobacco smoke-induced inflammation by modulating expression of chemokines and cytokines. Pulmonary Pharmacology & Therapeutics. 53. 86–99. 4 indexed citations

Singh, Dave, Arjun Ravi, Katie Kane, Tess Schmalbach, & David L. Hava. (2018). The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology. 84(9). 2097–2105. 9 indexed citations

10.

Holz, Olaf, Heike Biller, Katie Kane, et al.. (2015). Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial. BMC Pharmacology and Toxicology. 16(1). 21–21. 5 indexed citations

11.

Arold, Stephen P., et al.. (2014). Calcium Restores the Macrophage Response to Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology. 52(6). 728–737. 15 indexed citations

12.

Garg, Salil, Mahak Sharma, Amit Tuli, et al.. (2011). Lysosomal Trafficking, Antigen Presentation, and Microbial Killing Are Controlled by the Arf-like GTPase Arl8b. Immunity. 35(2). 182–193. 152 indexed citations

13.

Hava, David L., Nicole N. van der Wel, Nadia Cohen, et al.. (2008). Evasion of peptide, but not lipid antigen presentation, through pathogen-induced dendritic cell maturation. Proceedings of the National Academy of Sciences. 105(32). 11281–11286. 43 indexed citations

14.

Leslie, David S., Christopher C. Dascher, David L. Hava, et al.. (2008). Serum lipids regulate dendritic cell CD1 expression and function. Immunology. 125(3). 289–301. 74 indexed citations

15.

Wel, Nicole N. van der, David L. Hava, Donna Fluitsma, et al.. (2007). M. tuberculosis and M. leprae Translocate from the Phagolysosome to the Cytosol in Myeloid Cells. Cell. 129(7). 1287–1298. 734 indexed citations breakdown →

16.

Hava, David L., Manfred Brigl, Peter van den Elzen, et al.. (2004). CD1 assembly and the formation of CD1–antigen complexes. Current Opinion in Immunology. 17(1). 88–94. 28 indexed citations

17.

Hava, David L., Julianna LeMieux, & Andrew Camilli. (2003). From nose to lung: the regulation behind Streptococcus pneumoniae virulence factors. Molecular Microbiology. 50(4). 1103–1110. 69 indexed citations

18.

Hava, David L., Carolyn Hemsley, & Andrew Camilli. (2003). Transcriptional Regulation in the Streptococcus pneumoniae rlrA Pathogenicity Islet by RlrA. Journal of Bacteriology. 185(2). 413–421. 80 indexed citations

19.

Hava, David L. & Andrew Camilli. (2001). Isolation and characterization of a temperature-sensitive generalized transducing bacteriophage for Vibrio cholerae. Journal of Microbiological Methods. 46(3). 217–225. 25 indexed citations

20.

Lee, Sang Ho, David L. Hava, Matthew K. Waldor, & Andrew Camilli. (1999). Regulation and Temporal Expression Patterns of Vibrio cholerae Virulence Genes during Infection. Cell. 99(6). 625–634. 232 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact